viewCardieX Ltd

CardieX halted ahead of material commercialisation agreement announcement

The securities will remain in a trading halt until Thursday, September 24 or when an announcement is released to the market.

Cardiex Ltd - Cardiex in trading halt ahead of pending material commercialisation agreement announcement
The company’s subsidiary ATCOR was recently granted a new patent by the European Patent Office

CardieX Ltd (ASX:CDX) has been granted a trading halt pending the company releasing an announcement in regard to the imminent signing of a material commercialisation agreement.

Unless the ASX decides otherwise, the securities will remain in a trading halt until the earlier of the start of normal trading on Thursday, September 24, 2020, or when the announcement is released to market.

Shares last traded at 4.9 cents and have been trading higher since closing at 2 cents on June 29.

New patent granted

Last week the company’s subsidiary ATCOR was granted a new patent by the European Patent Office (EPO) to protect the intellectual property (IP) for the company’s proprietary SphygmoCor technology used in cuff-based blood pressure devices.

Patent EP2566387 specifically covers non-invasively estimating the heart’s pressure and pressure waveform with features related to cardiac function and arterial properties using a conventional BP cuff inflated to low pressure.

The patent provides a non-invasive, simple, and operator-independent tool to clinically diagnose the cardiovascular system and estimate the risk of having heart disease which otherwise would require an invasive procedure.

Granting of the European patent follows similar patents already granted to the company in the United States and Japan with the new European patent in force until 2034.

Quick facts: CardieX Ltd

Price: 0.09 AUD

Market: ASX
Market Cap: $82.95 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CardieX Ltd named herein, including the promotion by the Company of CardieX Ltd in any Content on the Site, the Company receives from said...


CardieX Limited signs disruptive deal with Chinese medical device company Andon

CardieX Limited (ASX: CDX) CEO Craig Cooper joined Steve Darling from Proactive with news the company has entered a co-development and commercial partnership agreement with Andon. Andon is one of China’s largest manufacturers of home-use medical electronic devices. Cooper talks about the deal...

on 9/9/20

2 min read